A$1.61 million rights issue follows A$250,000 Zoono placement
Zoono Group is seeking up to A$1.61 million from a non-renounceable rights issue after completing a separate A$250,000 placement, with its offer document warning of material uncertainty around going concern. The funds are intended to support shelf-life extension projects, intellectual property and working capital, but investors face dilution and an unresolved legal case.
- A$1.61 million one-for-10 rights issue at $0.039 per share
- A$250,000 placement completed with an existing shareholder
- FY26 report cited A$1.54 million operating cash outflow and A$268,120 cash balance
- Non-participating shareholders face potential dilution of about 9.1%
- New Zealand Commerce Commission hearing set for June 2027
Add us as a preferred source on Google
Zoono launches rights issue after cash runway warning
Zoono Group Limited (ASX:ZNO) is asking shareholders for up to A$1.61 million while openly flagging the financial strain behind the raise. The company’s offer document says its FY26 financial report recorded an operating cash outflow of A$1.54 million and cash of just A$268,120 at 30 June 2026, with the auditor drawing attention to a material uncertainty related to going concern.
The capital raising follows a A$250,000 placement completed on 23 October at the same $0.039 issue price. That placement was made to an existing shareholder and brought shares on issue to 412.62 million before the rights issue. Zoono’s latest quarterly update had also reported NZ$77,000 in cash at the end of September and estimated funding for 0.67 quarters, after customer receipts of NZ$736,000 and an operating cash outflow of NZ$115,000. The new raise therefore arrives less as a leisurely expansion cheque than as a funding bridge for a business still trying to convert commercial progress into dependable cash generation.
One-for-ten offer carries dilution and control implications
Eligible shareholders are being offered one new share for every 10 held at $0.039, aiming to issue up to 41.26 million shares and lift the register to 453.88 million if fully subscribed. The offer price is below Zoono’s last reported market price of $0.050 on 21 October, although the company cautions that the market price is not a reliable indicator of where the shares may trade after the offer.
The rights are non-renounceable, meaning shareholders cannot sell them on ASX. Those who do not participate face potential dilution of about 9.1% if the issue is fully taken up. Managing director and major shareholder Paul Hyslop, who controls a 28.99% interest, intends to take up a substantial proportion of his entitlement, but has not committed to taking it all. If he takes up his full entitlement while other shareholders do not, his voting power could rise to 30.99%. The offer opens on 3 November and is scheduled to close on 17 November.
Shelf-life projects compete with corporate funding needs
Zoono plans to direct the money towards packaging for extending product shelf life, work in China and India, patents and intellectual property, working capital and corporate expenses. The largest allocations are A$350,000 for company secretarial, registry, ASX, audit, insurance and other costs; A$300,000 for shelf-life packaging; A$273,000 for working capital; and A$240,000 for directors’ fees.
That spending plan sits alongside a commercial program that has produced promising orders but uneven cash conversion. Zoono’s UK packaging orders were previously valued at NZ$600,000, while its September update described retailer, packaging and shipping-container programs across several markets. The offer document says the allocation may change and warns that if the issue is undersubscribed, the company may scale back operational objectives, starting with packaging and international shelf-life expansion.
Going concern and litigation remain live risks
Zoono says directors believe the group will be able to pay its debts as they fall due, based on forecasts of improving operating cash flow, cost controls, inventory realisation and access to further funding lines. But the document also states that an unsuccessful or incomplete offer could require further fundraising or a reduction in activity. It lists additional capital requirements, competition, customer retention, inventory and intellectual property among the material risks.
The company is also defending proceedings brought by the New Zealand Commerce Commission over allegedly unsubstantiated representations about its hand sanitiser and microbe shield surface spray products. Zoono says it believes it complied with its legal obligations and intends to defend the case; the hearing is scheduled for 14 June 2027. Any penalty and costs remain uncertain, but the case adds another potential demand on a balance sheet the rights issue is intended to strengthen.
Bottom Line?
The immediate test is not simply whether Zoono can raise A$1.61 million, but whether that money buys enough time for shelf-life projects to produce sustained cash receipts before another funding decision is required.
Questions in the middle?
- How much of the rights issue will shareholders take up, and what shortfall will remain for allocation?
- Will the shelf-life extension projects in China, India and other markets convert into recurring cash receipts quickly enough to improve the funding position?
- What financial impact, if any, will follow the New Zealand Commerce Commission hearing scheduled for June 2027?
Sources
2-
Offer Document - Rights Issue (opens in a new tab)Official market announcement. Zoono Group Limited · 23 Oct 2026 · zoono.com.au
-
Non-Renounceable Rights Issue (opens in a new tab)Official market announcement. Zoono Group Limited · 23 Oct 2026 · zoono.com.au